Outcomes of patients with a pretransplant history of early-stage melanoma

A history of melanoma within the preceding 5 years is commonly considered a contraindication to solid organ transplantation. We investigated how a pretransplant history of melanoma impacts patient survival and melanoma recurrence. Institutional Review Board approval was obtained, and Duke's retrospective database was used to identify 4552 patients who underwent a solid organ transplant at Duke University from 1 January 2001 to 31 December 2016. Data with regard to the transplant, melanoma characteristics, rejection episodes, and survival were recorded. Of 4552 patients who underwent a solid organ transplant, 12 (0.3%) had a history of melanoma before transplant (six with melanoma in situ and six with stage I disease). The median time between melanoma diagnosis and transplant was 4.13 years (range: 1.1–13.3 years). The study cohort consisted of four liver transplants, four lung transplants, one kidney transplant, one heart transplant, one small bowel transplant, and one multivisceral transplant. At the median follow-up time of 2.8 years, 10 (83.3%) patients were alive. In nonmelanoma cohorts, the 3-year survival is 70% for thoracic transplants, 78% for liver transplants, and 88% for kidney transplants. In well-selected patients with a history of early-stage melanoma and an appropriate time interval between melanoma treatment and transplant, post-transplant outcomes are favorable. Presented in part at the 41st Annual Southeastern Consortium for Dermatology and 2018 Meeting of the American Academy of Dermatology. Correspondence to Paul J. Mosca, MD, PhD, MBA, Department of Surgery, Duke Cancer Institute, Duke University Health System, DUMC 3966, 10 Bryan Searle Drive, 466G Seeley G Mudd, Durham, NC 27707, USA Tel: +1 919 684 4064; fax: +1 919 684 6044; e-mail: paul.mosca@duke.edu Received March 13, 2018 Accepted May 9, 2018 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2ItpWOK